Current Understanding of Bioanalytical Assay Reproducibility: Incurred Sample Reanalysis, Incurred Sample Stability, and Incurred Sample Accuracy

Handbook of LC-MS Bioanalysis: Best Practices, Experimental Protocols, and Regulations

Volumn , Issue , 2013, Pages 47-64

  Yadav, Manish S ^a   Shrivastav, Pranav S ^b   De Boer, Theo ^c   Wieling, Jaap ^d   Singhal, Puran ^a  

^a Alkem Laboratories Ltd   (India)

^b GUJARAT UNIVERSITY   (India)

^c Analytical Biochemical Laboratory   (Netherlands)

^d QPS Netherlands BV   (Netherlands)

Author keywords

Assay robustness; Bioanalytical assay reproducibility; Bioanalytical research; Incurred sample accuracy (ISA); Incurred sample reanalysis (ISR); Incurred sample stability (ISS); Systematic errors

Indexed keywords

METABOLITES; SYSTEMATIC ERRORS;

ASSOCIATED MATRICES; BIOANALYTICAL; BIOANALYTICAL ASSAYS; BIOLOGICAL SAMPLES; INCURRED SAMPLES; NEW APPROACHES; REANALYSIS; REPRODUCIBILITIES;

STABILITY;

EID: 84903207997     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118671276.ch5     Document Type: Chapter

References (63)

1. AAPS. Third Bioanalytical Workshop: Quantitative Bioanalytical MethodsValidation and Implementation. Crystal City,VA, 2006.
2. AAPS Workshop on Topics in GLP Bioanalysis: Assay Reproducibility for Incurred Samples. Crystal City, VA, 2008.
3. Bansal S. AAPS Bioanalytical Survey. Presented at: The AAPS Third Bioanalytical Workshop: Quantitative Bioanalytical Methods Validation and Implementation. Crystal City, VA, 2006a.
4. Bansal S. Repeat Bioanalysis selection and reporting. AAPSWorkshop: quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays, 2006b.
5. Bansal S, DeStefano A. Key Elements of bioanalytical method validation for small molecules. AAPS J 2007;9(2):E109-E114.
6. Bansal S. Did incurred sample reanalysis raise confidence in bioanalytical results? Presented at: The AAPSWorkshop on Topics in GLP Bioanalysis: Assay Reproducibility for Incurred Samples. Crystal City, VA, 2008.
7. Bansal S, Arnold M, Garofolo F. International harmonization of bioanalytical guidance. Bioanalysis 2010;2(4):685-687.
8. Barfield M, Ahmed S, Busz M. GlaxoSmithKline's experience of incurred sample reanalysis for dried blood spot samples. Bioanalysis 2011;3(9):1025-1030.
9. Bérubé ER, Taillon MP, Milton Furtado M, Garofolo F. Impact of sample hemolysis on drug stability in regulated bioanalysis. Bioanalysis 2011;3(18):2097-2105.
10. Bland JM, Altman DG. Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet 1995;346:1085-1087.
11. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999;8:135-160.
12. Briscoe CJ, Hage DS. Factors affecting the stability of drug and drug metabolites in biological matrices. Bioanalysis 2009;1(1): 205-220.
13. Bryan PD. What is incurred sample analysis and why is it important? AAPS Newsmagazine 2008;11(9):18-22.
14. Cote C, Lahaie M, Latour S, et al. Impact of methylation of acyl glucuronide metabolites on incurred sample reanalysis evaluation: ramiprilat case study. Bioanalysis 2011;3(9):951-965.
15. De Boer T, Wieling J. Incurred sample accuracy assessment: design of experiments based on standard addition. Bioanalysis 2011;3(9):983-992.
16. Dicaire C, Berube E-R, Dumont I, Furtado M, Garofolo F. Impact of oxcarbazepine sulphate metabolite on incurred sample reanalysis and quantification of oxcarbazepine. Bioanalysis 2011;3(9):973-982.
17. Eastwood BJ, FarmenMW,Iversen PW, et al. The minimum significant ratio: a statistical parameter to characterize the reproducibility of potency estimates from concentration-response assays and estimation by replicate-experiment studies. J Biomol Screen 2006;11(3):253-261.
18. European Medicines Agency (EMA). Committee for medicinal products for human use, guidelines on validation of bioanalytical methods (draft), EMA/CMP/EWP/192217/2011. Available at www.ema. europa.eu/ema. Accessed Apr 10, 2013.
19. Fast DM, KelleyM, Viswanathan CT, et al. AAPSworkshop on current topics in GLP bioanalysis: assay reproducibility for incurred samples-implications of Crystal City recommendations. AAPS J 2009;11(2):238-241.
20. Freisleben A, Brudny-Koppel M, Mulder H, de Vries R, de Zwart M, Timmerman P. Blood stability testing: European Bioanalysis Forum view on current challenges for regulated bioanalysis. Bioanalysis 2011;3(12):1333-1336.
21. Fu Y, Li W, Smith HT, Tse FLS. An investigation of incurred human urine sample reanalysis failure. Bioanalysis 2011;3(9): 967-972.
22. Garofolo F. How to manage having no incurred sample reanalysis evaluation failures. Bioanalysis 2011;3(9):935-938.
23. Gupta A, Singhal P, Shrivastav PS, Sanyal M. Application of a validated ultra performance liquid chromatography-tandem mass spectrometry method for the quantification of darunavir in human plasma for a bioequivalence study in Indian subjects. J Chromatogr B 2011;879(24):2443-2453.
24. Health Canada. Guidance to Industry. Conduct and Analysis of Bioavailability and Bioequivalence Studies-Part A: Oral Dosage Formulations Used for Systemic Effects, 1992. Available at www.hc-sc.gc.ca/dhp-mps/prodpharma/applicdemande/guide-ld/bio/bio-a-eng.php. Accessed Mar 1, 2013.
25. Health Canada. Notice to industry-removal of requirement for 15% random replicate sample notice affecting guideline A and guideline B requirements, 2003. Available at www.hc-sc.gc.ca/dhpmps/alt_formats/hpfb-dgpsa/pdf/prodpharma/15rep-eng.pdf. Accessed Mar 1, 2013.
26. Hill H. Developing trends in bioanalysis. Bioanalysis 2009; 1(8):1359-1364.
27. James CA, Hill HM. Procedural elements involved in maintaining bioanalytical data integrity for good laboratory practices studies and regulated clinical studies. AAPS J 2007;9(2): E123-E127.
28. Kelley M, DeSilva B. Key elements of bioanalytical method validation for macromolecules. AAPS J 2007;9(2): E156-E163.
29. Kelley M. Incurred sample reanalysis: it is just a matter of good scientific practice. Bioanalysis 2011;3(9):931-932.
30. Larsson M, Han F. Determination of rifalazil in dog plasma by liquid-liquid extraction and LC-MS/MS: Quality assessment by incurred samples. J Pharm Biomed Anal 2007;45(4): 616-624.
31. Lowes S, Jersey J, Shoup R, et al. Recommendations on: internal standard criteria, stability, incurred sample reanalysis and recent 483s by the Global CRO council for bioanalysis. Bioanalysis 2011;3(12):1323-1332.
32. Lytle FE, Julian RK, Tabert AM. Incurred sample reanalysis: enhancing the Bland-Altman approach with tolerance intervals. Bioanalysis 2009;1(4):705-714.
33. Massart DL, Vandeginste BGM, Deming SN, Michotte Y, Kaufman L. Chemometrics: A Textbook, 1st ed. Amsterdam, The Netherlands: Elsevier; 1988.
34. Meng M, Reuschel S, Bennett P. Identifying trends and developing solutions for incurred sample reanalysis failure investigations in a bioanalytical CRO. Bioanalysis 2011;3(4):449-465.
35. Nowatzke W, Woolf E. Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls and study samples. AAPS J 2007;9(2):E117-E122.
36. Parekh JM,Vaghela RN, Sutariya DK, Sanyal M,YadavM, Shrivastav PS. Chromatographic separation and sensitive determination of teriflunomide, an active metabolite of leflunomide in human plasma by liquid chromatography tandem mass spectrometry. J Chromatogr B 2010;878(24):2217-2225.
37. Patel DS, Sharma N, Patel MC, Patel BN, Shrivastav PS, Sanyal M. Analysis of a second-generation tetracycline antibiotic minocycline in human plasma by LC-MS/MS. Bioanalysis 2011a;3(19):2177-2194.
38. Patel DS, Sharma N, Patel MC, Patel BN, Shrivastav PS, Sanyal M. Development and validation of a selective and sensitive LC-MS/MS method for determination of cycloserine in human plasma: Application to bioequivalence study. J Chromatogr B 2011b;879(23):2265-2273.
39. Petersen PH, Stöckl D, Blaabjerg O, et al. Graphical interpretation of statistical data from comparison of a field method with reference method by use of difference plots. Clin Chem 1997;43(11):2039-2046.
40. Rocci ML Jr., Collins E, Wagner-Caruso KE, Gibbs AD, Fellows DG. Investigation and resolution of incurred sample reanalysis failures: two case studies. Bioanalysis 2011;3(9):993-1000.
41. Rocci ML, Devanarayan V, Haughey DB, Jardieu P. Confirmatory reanalysis of incurred bioanalytical sample. AAPS J 2007;9(3):E336-E343.
42. Sailstad JM, Salfen BE, Bowsher RR. Incurred sample reanalysis: failures in macromolecules analysis-insight into possible causes. Bioanalysis 2011;3(9):1001-1006.
43. Savoie N, Garofolo F, van Amsterdam P, et al. White paper on recent issues in regulated bioanalysis & global harmonization of bioanalytical guidance. Bioanalysis 2010;2(12):1945-1960.
44. Sennbro CJ, Knutsson M, Timmerman P, van Amsterdam P. Anticoagulant counter ion impact on bioanalytical LC-MS/MS assay performance: additional validation required? Bioanalysis 2011;3(21):2389-2391.
45. Shah VP. The history of bioanalytical method validation and regulation: Evolution of a guidance document on bioanalytical methods validation. AAPS J 2007;9(1):E43-E47.
46. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. Pharm Res 1992;9(4):588-592.
47. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation- a revisit with a decade of progress. Pharm Res 2000;17(12):1551-1557.
48. Smith G. Bioanalytical method validation: notable points in the 2009 draft EMA guideline and differences with the 2001 FDA guidance. Bioanalysis 2010;2(5):929-935.
49. Tan A, Gagnon-Carignan S, Lachance S, Boudreau N, Levesque A, Masse R. Beyond successful ISR: case-by-case investigations for unmatched reassay results when ISR passed. Bioanalysis 2011;3(9):1031-1038.
50. Thway TM, Macaraeg CR, Calamba D, et al. Bioanalytical method requirements and statistical considerations in incurred sample reanalysis for macromolecules. Bioanalysis 2010;2(9):1587-1596.
51. Timmerman P, Luedtke S, van Amsterdam P, Brudny-Kloeppel M, Lausecker B. Incurred sample reproducibility: views and recommendations by the European Bioanalysis Forum. Bioanalysis 2009;1(6):1049-1056.
52. Timmerman P, White S, Globig S, Ludtke S, Brunet L, Smeraglia J. EBF recommendation on the validation of bioanalytical methods for dried blood spots. Bioanalysis 2011;3(14):1567-1575.
53. US FDA. Guidance for industry bioanalytical method validation. US Department of Health and Human Services, FDA Centre for Drug Evaluation and Research, MD, 2001.
54. Viswanathan CT, Bansal S, Booth B, et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J 2007;9(1):E30-E42.
55. Viswanathan CT. Incurred sample reanalysis: a global transformation. Bioanalysis 2011;3(23):2601-2602.
56. Voicu V, Gheorghe MC, Sora ID, Ŝarbu C, Medvedovici A. Incurred sample reanalysis: different evaluation approaches on data obtained for spironolactone and its active metabolite canrenone. Bioanalysis 2011;3(12):1343-1356.
57. Yadav M, Gupta A, Singhal P, Shrivastav PS. Development and validation of a selective and rapid liquid chromatography tandem mass spectrometry method for the quantification of abacavir in human plasma. J Chromatogr Sci 2010a;48(8):654-662.
58. Yadav M, Rao R, Kurani H, et al. Validated ultra high performance liquid chromatography-tandem mass spectrometry method for the determination of pramipexole in human plasma. J Chromatogr Sci 2010b;48(10):811-818.
59. Yadav M, Shrivastav PS. Incurred sample reanalysis (ISR): a decisive tool in bioanalytical research. Bioanalysis 2011;3(9):1007-1024.
60. Yadav M, Singhal P, Goswami S, Pande UC, Sanyal M, Shrivastav PS. Selective determination of antiretroviral agents tenofovir, emtricitabine and lamivudine in human plasma by a validated liquid chromatography tandem mass spectrometry method for bioequivalence study in healthy Indian subjects. J Chromatogr Sci 2010c;48(9):704-713.
61. Yadav M, Trivedi V, Upadhyay V, et al. Comparison of extraction procedures for assessment of matrix effect for selective and reliable determination of atazanavir in human plasma by LC-ESI-MS/MS. J Chromatogr B 2012. Forthcoming. DOI: 10.1016/j.jchromb.2011.12.031.
62. Yadav M, Upadhyay V, Chauhan V, et al. Chromatographic separation and simultaneous determination of tolterodine and its active metabolite, 5-hydroxymethyl tolterodine in human plasma by LC-ESI-MS/MS. Chromatographia 2010d;72(3-4):255-264.
63. Yadav M, Upadhyay V, Singhal P, Goswami S, Shrivastav PS. Stability evaluation and sensitive determination of antiviral drug, valacyclovir and its metabolite acyclovir in human plasma by a rapid liquid chromatography-tandem mass spectrometry method. J Chromatogr B 2009;877(8-9):680-688.